SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0
http://www.w3.org/2000/01/rdf-schema#comment
"Findings indicate that ASP3026 has potential efficacy for non-small cell lung cancer (NSCLC) and is expected to improve the therapeutic outcomes of patients with cancer with anaplastic lymphoma receptor tyrosine kinase (ALK) abnormality."
xsd:string
http://purl.uniprot.org/uniprot/#_EE4643745FF07DF407C0D0A90CF120B37836D6287364D403BB3965BAAB45B7A8E3A5296DFAEDD010251B43F007640BF6
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0
http://purl.uniprot.org/uniprot/D1MAM1
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0
http://purl.uniprot.org/uniprot/#_D1MAM1-mappedCitation-24419060
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/5FD906BA7499BD5B96E126A8A2F7C47203E7EFC011632EB59FEB3BF4F768D2F195D0959B8BEFE7C3285CA0E59FA87AE0